AUTHOR=Li Zi-Yun , Chi Chao-Cheng , Cai Sui-Qing 

TITLE=Case Report: Morbihan disease treated with tofacitinib successfully

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1177316

DOI=10.3389/fimmu.2023.1177316

ISSN=1664-3224

ABSTRACT=To date, there is no standard treatment for Morbihan disease. Several studies have reported that Morbihan disease responds well to systemic corticosteroids (prednisone and prednisolone, systemic antibiotics (tetracyclines), antihistamines (ketotifen), and surgical therapy (Lymphaticovenous anastomosis). To our knowledge, Tofacitinib, as a Janus Kinase  (JAK) inhibitor, plays a vital role in the treatment of inflammatory and autoimmune disorders. Therefore, Tofacitinib may be a promising medical option for patients with Morbihan disease.